Completed PHASE3 INTERVENTIONAL 2-arm NCT00185159

Olmesartan Medoxomil in Diabetes Mellitus

Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)

Sponsor: Sankyo Pharma Gmbh

Conditions Cardiovascular Disease Diabetes Mellitus, Type 2 Kidney Disease

Interventions Olmesartan medoxomil Placebo Tablets

Updated 9 times since 2017 Last updated: Jan 19, 2010 Started: Oct 31, 2004 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00185159, this PHASE3 trial focuses on Cardiovascular Disease and Diabetes Mellitus, Type 2 and remains completed. Sponsored by Sankyo Pharma Gmbh, it has been updated 9 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

9 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Sep 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sankyo Pharma Gmbh

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Darmstadt, Germany